highlight
human
mab
two
epitop
specif
bind
cooper
ebolaviru
gp
cooper
mediat
mab
enhanc
bind
vulner
gp
epitop
twomab
cocktail
exhibit
enhanc
potenc
heterolog
ebolavirus
two
mgkg
dose
cocktail
fulli
protect
nonhuman
primat
nhp
challeng
ebov
summari
structur
principl
underli
composit
protect
antivir
monoclon
antibodi
mab
cocktail
poorli
defin
exploit
antibodi
cooper
develop
therapeut
mab
cocktail
ebola
viru
systemat
analyz
antibodi
repertoir
human
survivor
identifi
pair
potent
neutral
mab
cooper
bound
ebolaviru
glycoprotein
gp
highresolut
structur
reveal
twoantibodi
cocktail
molecular
mimicri
major
featur
mabgp
interact
broadli
neutral
mab
target
conserv
epitop
gp
base
region
mab
bound
glycan
cap
epitop
possess
neutral
fcmediat
effector
function
activ
potenti
neutral
remodel
glycan
cap
structur
cocktail
enabl
enhanc
gp
bind
viru
neutral
cocktail
demonstr
resist
viru
escap
protect
nonhuman
primat
nhp
ebola
viru
diseas
data
illumin
structur
principl
antibodi
cooper
implic
develop
antivir
immunotherapeut
correspond
jamescrow
vumcorg
cooper
interact
monoclon
antibodi
mab
viral
antigen
poorli
understood
gilchuk
et
al
perform
structur
function
analysi
cooper
cocktail
two
human
mab
recogn
major
epitop
ebolaviru
glycoprotein
gp
defin
cooper
bind
gp
mechan
enhanc
ebolaviru
neutral
human
monoclon
antibodi
mab
promis
therapeut
molecul
use
prevent
treatment
viral
infecti
diseas
recent
year
advanc
human
b
cell
isol
techniqu
led
identif
larg
number
therapeut
mab
candid
mani
lifethreaten
viral
pathogen
target
includ
antigen
variabl
virus
human
immunodefici
viru
hiv
sok
burton
influenza
viru
laursen
wilson
newli
emerg
pathogen
high
epidem
potenti
includ
ebola
viru
bornholdt
et
al
marburg
viru
flyak
et
al
zika
viru
sapparapu
et
al
stettler
et
al
wang
et
al
lassa
viru
robinson
et
al
middl
east
respiratori
syndrom
coronaviru
merscov
corti
et
al
poxvirus
gilchuk
et
al
nipah
viru
geisbert
et
al
mani
medic
import
virus
antivir
human
mab
evalu
human
therapeut
clinic
trial
walker
burton
includ
sever
ebolaviru
therapi
nih
antibodi
mediat
protect
direct
viru
neutral
andor
engag
innat
immun
cell
via
fc
receptor
fcr
crow
lu
et
al
potent
neutral
broad
reactiv
protect
capac
desir
mab
featur
could
use
select
lead
develop
monotherapi
cocktail
cocktail
might
offer
greater
efficaci
resist
viral
escap
corti
et
al
keeff
et
al
wec
et
al
molecular
structur
basi
optim
combin
mab
illdefin
current
mab
discoveri
approach
typic
focus
antibodi
variabl
fragment
fv
regionmedi
biolog
function
singl
isol
mab
eg
bind
neutral
fcregionmedi
effector
function
walker
burton
molecular
interact
two
mab
recogn
antigen
enhanc
eg
cooper
synergist
fashion
less
well
investig
interact
might
contribut
greatli
overal
efficaci
protect
cocktail
carlsen
et
al
doriaros
et
al
howel
et
al
mascola
et
al
one
key
challeng
imped
progress
area
structur
determin
cooper
neutral
antibodi
poorli
understood
develop
synergist
mab
cocktail
virus
high
antigen
variabl
includ
hiv
hepat
c
noroviru
influenza
viru
ebola
viru
also
thwart
fact
small
subset
virusspecif
mab
avail
incorpor
cocktail
broadli
crossreact
field
strain
anoth
challeng
rel
small
number
mab
combin
test
iter
therapeut
efficaci
given
high
cost
labor
vivo
viru
challeng
studi
especi
nonhuman
primat
nhp
larg
anim
model
test
need
therefor
ration
develop
antivir
therapeut
mab
cocktail
import
implement
approach
identifi
combin
mab
optim
molecular
interact
formul
cocktail
along
structur
function
analysi
defin
featur
mediat
effici
protect
mab
studi
describ
design
cooper
twoantibodi
cocktail
possess
neutral
activ
primari
ebolavirus
respons
outbreak
humansebola
ebov
bundibugyo
bdbv
sudan
sudv
virus
kuhn
ebov
caus
sever
diseas
human
case
fatal
rate
signific
epidem
potenti
largest
epidem
date
occur
west
africa
total
case
ebola
viru
diseas
evd
death
report
coltart
et
al
new
ongo
outbreak
democrat
republ
congo
drc
cdc
highlight
need
acceler
develop
evd
therapeut
park
et
al
urbanowicz
et
al
ebolaviru
envelop
e
contain
singl
surfac
protein
glycoprotein
gp
major
target
neutral
mab
lee
saphir
conduct
analysi
human
mab
gp
identifi
two
class
broadli
reactiv
mab
cooper
bind
gp
neutral
viru
highresolut
structur
illumin
mechan
cooper
twoantibodi
cocktail
offer
protect
mice
antigen
diverg
viru
sudv
demonstr
high
therapeut
efficaci
live
ebov
challeng
nhp
find
offer
ration
strategi
develop
potent
twoantibodi
cocktail
design
base
structur
featur
mab
interact
ebolaviru
gp
previou
work
identifi
two
potent
therapeut
candid
mab
immunoglobulin
subclass
subclass
b
cell
human
survivor
evd
mab
bind
conserv
epitop
base
gp
neutral
three
ebolavirus
caus
diseas
human
ebov
sudv
bdbv
protect
mice
challeng
ebov
offer
partial
protect
bdbv
sudv
work
also
reveal
class
noncompet
glycancapregionspecif
mab
enhanc
bind
gp
cooper
manner
suggest
strategi
twoantibodi
cocktail
design
screen
gpreactiv
human
mab
identifi
two
previous
describ
glycancapspecif
gilchuk
et
al
one
addit
mab
origin
suitabl
partner
design
cooper
twoantibodi
cocktail
figur
tabl
partner
candid
mab
filter
basi
neutral
activ
wildtyp
wt
ebolaviru
ebov
least
broad
reactiv
ebov
bdbv
sudv
gp
cooper
enhanc
bind
ebov
gp
capac
protect
ebov
challeng
mice
potenti
util
mab
compon
therapeut
cocktail
sought
character
depth
cooper
effect
mediat
combin
two
mab
first
partner
cocktail
chose
wellcharacter
baseregionspecif
mab
express
variabl
gene
sequenc
mab
chines
hamster
ovari
cho
cell
recombin
fc
mutant
molecul
lala
diminish
fc
effector
function
lala
possess
highest
protect
efficaci
lowdos
treatment
ebov
mice
act
princip
via
neutral
protect
ebov
second
cocktail
partner
mab
potent
neutral
ebov
show
highest
activ
three
identifi
cooper
glycancapspecif
mab
cooper
bind
gp
partner
mab
produc
function
compet
design
engag
fc
region
might
import
protect
gp
glycancapspecif
mab
assess
fcmediat
kill
antigenexpress
cell
engin
variant
use
stabli
transfect
ebovgpexpress
snaptag
cell
line
target
heterolog
human
peripher
blood
mononuclear
cell
pbmc
sourc
effector
cell
snaptag
selflabel
protein
tag
allow
specif
label
target
cell
line
fluoresc
dye
facilit
detect
effectorcellmedi
kill
activ
flow
cytometri
domi
et
al
lala
show
low
cytotox
activ
compar
control
wt
mediat
effici
cell
kill
compar
recombin
form
glycancapdirect
mab
includ
zmapp
tm
cocktail
figur
davidson
et
al
similar
function
profil
two
mab
obtain
use
beador
solidphaseimmobil
gp
ectodomain
variou
human
effector
cell
figur
find
confirm
rel
high
capac
engag
fc
diminish
fc
function
lala
next
studi
util
two
fc
form
next
assess
neutral
activ
individu
mab
potent
neutral
three
ebolavirus
wherea
potent
neutral
ebov
bdbv
figur
howev
mab
broadli
reactiv
measur
bind
recombin
gp
ectodomain
bind
fulllength
ebov
bdbv
sudv
gp
display
surfac
stabli
transduc
jurkat
cell
line
figur
test
mab
bind
three
jurkat
gp
cell
line
treatment
thermolysin
mimic
endosom
cathepsin
cleavag
creat
membranedisplay
cleav
gp
gp
cl
bound
weakli
intact
gp
strongli
gp
cl
demonstr
satur
doserespons
curv
increas
bind
gp
cl
intact
gp
figur
effici
bind
gp
cl
concord
higher
neutral
activ
viru
display
ebov
gp
cl
viru
intact
ebov
gp
describ
previou
c
b
figur
candid
cocktail
human
mab
exhibit
differenti
fcmediat
activ
broadli
neutral
ebolavirus
differenti
recogn
gp
vitro
kill
capac
curv
variant
mab
determin
use
snaptag
ebov
gpexpress
cell
line
target
human
pbmc
sourc
effector
cell
dot
line
indic
assay
background
b
ebov
bdbv
sudv
neutral
virus
encod
enhanc
green
fluoresc
protein
egfp
incub
increas
concentr
purifi
mab
infect
determin
day
inocul
measur
egfp
fluoresc
cell
c
bind
candid
mab
intact
cellsurfacedisplay
ebov
gp
solid
shape
cleav
ebov
gp
cl
open
shape
fluoresc
label
mab
incub
suspens
cell
jurkat
cell
line
stabli
transduc
ebov
gp
jurkatebov
gp
cell
treat
thermolysin
cleav
gp
jurkatebov
gp
cl
bind
assess
flow
cytometri
dot
line
black
indic
dynam
rang
mab
bind
gp
dash
line
show
estim
curv
slope
base
constraint
satur
bind
valu
mean
sd
n
least
two
independ
experi
shown
c
see
also
figur
tabl
figur
mab
cocktail
cooper
enabl
enhanc
gp
bind
viru
neutral
vivo
protect
class
averag
fabebov
gp
complex
neg
stain
em
demonstr
simultan
bind
orang
blue
gp
b
bind
jurkatebov
gp
assess
flow
cytometri
use
alexa
fluor
label
mab
alon
solid
shape
mab
titrat
fix
concentr
mgml
unlabel
partner
mab
open
shape
indic
satur
bind
estim
figur
effect
mab
composit
assess
twoway
anova
arrow
show
comparison
estim
foldincreas
bind
c
concentrationdepend
potenti
gp
bind
partner
mab
assess
b
use
singl
concentr
label
mab
alon
label
mab
mixtur
increas
concentr
unlabel
partner
mab
indic
fold
increas
bind
gp
shown
number
orang
potenti
neutral
sudv
viru
incub
increas
concentr
alon
gray
titrat
subneutr
concentr
mgml
green
percent
sudv
neutral
alon
shown
dot
line
p
valu
estim
comparison
ic
valu
student
test
legend
continu
next
page
studi
glycancapspecif
bound
moder
less
effici
intact
cellsurfacedisplay
gp
compar
bind
recombin
gp
figur
togeth
result
defin
bind
function
featur
cocktail
candid
mab
show
exposur
epitop
limit
intact
gp
three
ebolavirus
mab
cocktail
cooper
enabl
enhanc
gp
bind
viru
neutral
vivo
protect
neg
stain
electron
microscopi
em
analysi
show
bind
gp
simultan
figur
character
cooper
effect
two
mab
cocktail
first
assess
gp
bind
mab
presenc
absenc
partner
mab
fluoresc
label
titrat
constant
concentr
unlabel
partner
mab
previous
describ
rel
fluoresc
bind
label
mab
intact
cellsurfacedisplay
ebov
bdbv
sudv
gp
determin
constant
concentr
mgml
enhanc
bind
gp
three
ebolavirus
compar
bind
alon
cooper
mediat
minor
effect
bind
gp
figur
cooper
bind
intact
homolog
ebov
gp
increas
steadili
increas
concentr
higher
alon
figur
indic
higher
dose
would
necessari
leverag
strong
cooper
effect
twoantibodi
cocktail
bind
intact
gp
cocktail
fulli
match
strong
satur
bind
proteolyt
prime
gp
cl
figur
therefor
bind
partial
enhanc
access
base
epitop
intact
gp
recognit
compar
access
epitop
gp
cl
next
assess
whether
cooper
bind
confer
enhanc
neutral
activ
cocktail
use
first
antigen
diverg
viru
sudv
fulli
neutral
sudv
neutral
sudv
modest
potenc
figur
consist
observ
increas
cooper
bind
sudv
gp
figur
subneutr
concentr
potenti
neutral
activ
chimer
viru
display
sudv
gp
reduc
halfmaxim
inhibitori
concentr
ic
valu
figur
neutral
cocktail
synergist
determin
chou
talalay
method
estim
combin
index
ci
defin
effect
drug
combin
addit
effect
ci
synerg
ci
antagon
ci
chou
also
demonstr
synergi
neutral
viru
homolog
ebov
gp
use
cocktail
mixtur
figur
togeth
data
support
find
cooper
bind
gp
next
test
whether
potenti
protect
cocktail
sudv
vivo
use
stringent
mous
challeng
model
provid
uniform
lethal
raymond
et
al
irrelev
mab
denv
isotyp
specif
dengu
viru
e
protein
fibriansah
et
al
use
control
sudvchalleng
mice
treat
mgkg
mab
alon
neutral
sudv
day
infect
succumb
diseas
day
infect
similarli
anim
control
group
treatment
alon
delay
mortal
howev
anim
surviv
treatment
cocktail
mixtur
confer
higher
protect
anim
surviv
associ
p
valu
mantelcox
test
compar
treatment
alon
figur
result
show
complement
activ
sudv
vivo
unknown
whether
protect
model
predict
protect
sudv
nhp
use
antibodi
cocktail
attract
approach
avoid
high
risk
viru
escap
rna
viru
inher
monotherapi
approach
hypothes
cocktail
counteract
escap
effici
individu
mab
mab
possess
independ
neutral
activ
ebov
bdbv
least
togeth
exhibit
enhanc
activ
use
highthroughput
quantit
realtim
cell
analysi
assay
rtca
measur
virusinduc
cytopath
effect
screen
escap
mutat
presenc
individu
mab
cocktail
figur
recombin
vesicular
stomat
virus
rvsv
display
ebov
gp
rvsv
ebov
gp
sudv
gp
rvsvsudv
gp
incub
presenc
increas
mab
concentr
assess
neutral
repeat
passag
vero
cell
monolay
cultur
virus
escap
neutral
assess
suscept
neutral
individu
mab
cocktail
gene
encod
gp
sequenc
confirm
presenc
escap
mutat
fifteen
consecut
passag
identifi
two
rvsvebov
gp
mutant
escap
neutral
one
rvsvsudv
gp
mutant
escap
neutral
mutant
detect
select
presenc
individu
mab
mutat
identifi
within
predict
epitop
respect
mab
tabl
viru
escap
detect
passag
presenc
cocktail
confirm
neutral
late
passag
e
cooper
enhanc
protect
sudv
infect
mice
mice
inocul
wt
sudv
treat
dpi
mgkg
alon
mgkg
alon
mgkg
cocktail
mixtur
mab
mab
denv
control
surviv
top
combin
clinic
score
middl
combin
bodi
weight
bottom
surviv
mice
shown
indic
group
compar
use
mantelcox
test
indic
anim
found
dead
prior
reach
predetermin
clinic
score
data
pool
two
three
independ
experi
mean
sd
n
least
two
independ
experi
shown
b
see
also
figur
tabl
virus
individu
mab
rvsvebov
gp
mutant
escap
neutral
isol
neutral
fulli
alon
cocktail
show
one
neutral
mab
lose
activ
viru
variant
escap
mutat
neutral
mab
cocktail
maintain
activ
tabl
data
strongli
suggest
use
cocktail
enhanc
effect
neutral
potenc
mab
counteract
viru
escap
homolog
ebov
although
escap
detect
cocktail
escap
mutant
identifi
rvsvsudv
gp
conserv
residu
ebov
bdbv
sudv
gp
fulli
neutral
either
mab
alon
cocktail
suggest
possibl
escap
heterolog
sudv
therefor
cooper
gp
bind
cocktail
could
benefit
therapeut
effect
enhanc
viru
neutral
enhanc
vivo
protect
reduc
risk
viru
escap
cocktail
mab
recogn
rel
conserv
epitop
two
major
antigen
site
gp
previous
report
neg
stain
em
reconstruct
complex
gp
epitop
yet
character
perform
neg
stain
em
studi
use
complex
fab
alon
combin
fab
recombin
trimer
ebov
gp
dtm
recogn
glycan
cap
region
bound
nearli
perpendicular
surfac
gp
figur
similar
bind
pose
also
made
interact
interior
chalic
within
outer
domain
glycan
cap
howev
enhanc
bind
wherea
data
shown
defin
key
contact
residu
epitop
use
alanin
scan
mutagenesi
gp
test
bind
individu
member
shotgun
mutagenesi
alanin
mutat
librari
ebov
gp
display
cell
also
gener
antibodi
escap
mutant
ebov
virus
determin
gp
sequenc
mutat
reduc
bind
gp
figur
escap
mutat
reduc
neutral
potenc
key
contact
residu
posit
top
glycan
cap
within
region
rel
low
sequenc
conserv
howev
five
seven
contact
residu
conserv
among
ebov
bdbv
sudv
gp
ebov
gp
residu
nonconserv
explain
broad
reactiv
togeth
studi
identifi
site
vulner
antibodi
recognit
glycan
cap
mediat
crossreact
cooper
bind
cocktail
next
defin
structur
determin
gp
bind
reactiv
breadth
resolv
crystal
structur
fab
complex
ebov
gp
cl
f
resolut
base
protom
gp
cl
constant
domain
orient
upward
viral
membran
figur
footprint
includ
rel
conserv
region
includ
intern
fusion
loop
ifl
stem
subunit
hydrophob
pocket
form
five
residu
subunit
term
previous
pocket
zhao
et
al
west
et
al
footprint
distinct
previous
describ
broad
human
basespecif
mab
murin
et
al
west
et
al
similar
footprint
potent
humanbasespecif
mab
figur
fulli
neutral
ebov
bdbv
sudv
wec
et
al
west
et
al
bound
pocket
ifl
stem
region
fusion
loop
unlik
human
mab
bind
hydrophob
loop
end
structur
bridg
neighbor
gp
protom
king
et
al
howev
like
gain
reactiv
sudv
footprint
slightli
higher
gp
base
differ
angl
approach
direct
downward
toward
viral
membran
figur
contrast
direct
upward
membran
west
et
al
footprint
allow
mab
avoid
contact
nonconserv
ebov
gp
residu
sudv
gp
interfac
figur
key
contact
residu
bind
complementar
determin
region
heavi
chain
west
et
al
find
highlight
variabl
epitop
lead
therapeut
candid
mab
identifi
distinct
repres
among
class
pockettarget
mab
extend
activ
sudv
analysi
fabgp
cl
crystal
structur
identifi
gp
cl
residu
interfac
fab
locat
amino
acid
aa
ten
locat
aa
interact
conform
epitop
interfac
make
direct
contact
aa
aa
residu
rel
conserv
among
ebov
bdbv
sudv
figur
bound
pocket
gp
cl
form
residu
contact
residu
four
seven
contact
line
bottom
part
pocket
figur
unbound
fulllength
gp
pocket
normal
occupi
flexibl
descend
loop
glycan
cap
residu
imped
access
pocket
like
west
et
al
either
bound
conform
gp
loop
displac
activ
displac
pocket
upon
bind
loop
present
gp
cl
remov
cleavag
use
hydrogendeuterium
exchang
mass
spectrometri
hdxm
compar
deuterium
label
peptid
gener
digest
gp
gp
cl
pepsin
decreas
label
gp
pocket
residu
involv
interfac
confirm
limit
access
epitop
structur
intact
gp
trimer
figur
cleavag
remov
glycan
cap
loop
expos
pocket
explain
enhanc
bind
gp
cl
figur
enhanc
neutral
potenc
mab
virion
bear
gp
cl
compar
intact
gp
previou
work
suggest
bind
nonneutr
macaqu
mab
loop
displac
loop
caus
unmask
neutral
epitop
mab
gp
base
howel
et
al
west
et
al
howev
unlik
figur
bind
site
includ
pocket
fulli
expos
gp
cl
mask
loop
intact
gp
enlarg
view
show
occup
pocket
gp
residu
ten
residu
tip
shown
orang
cartoon
ebov
gp
cl
shown
surfac
represent
cyan
yellow
pocket
residu
involv
interfac
show
decreas
hydrogendeuterium
bind
uncleav
gp
determin
hdxm
map
onto
surfac
light
red
light
yellow
b
individu
alanin
mutat
six
residu
loop
increas
bind
mab
gray
bar
affect
bind
recombin
form
gp
base
mab
white
bar
identifi
top
mean
rang
half
maximum
minu
minimum
valu
least
two
replic
data
point
shown
posit
identifi
residu
loop
green
shown
ebov
gp
pdb
gray
sphere
bottom
see
also
figur
crystal
structur
apoebov
gp
dmucdtm
pdb
region
red
loop
green
right
ebov
cryoem
structur
loop
shown
blue
legend
continu
next
page
whose
bind
fulli
abolish
sever
alanin
mutat
loop
howel
et
al
none
alanin
mutat
within
loop
reduc
bind
gp
data
shown
rather
alanin
substitut
sever
residu
loop
distal
epitop
upper
portion
glycan
cap
increas
bind
compar
bind
wildtyp
gp
figur
suggest
bind
loop
bind
loop
requir
cooper
enhanc
bind
determin
structur
determin
cooper
within
cocktail
solv
cryogen
em
cryoem
structur
fab
complex
ebov
gp
glycan
cap
intact
mucinlik
domaindelet
dmuc
resolut
figur
tabl
determin
contribut
cooper
also
solv
cryoem
structur
fab
alon
complex
ebov
gp
dmuc
resolut
figur
tabl
unabl
solv
structur
glycan
cap
region
complex
fab
alon
cryoem
data
shown
like
due
flexibl
glycan
cap
unlik
previous
describ
mab
structur
reveal
bind
directli
loop
instead
loop
directli
interact
strand
residu
form
extend
beta
sheet
glycan
cap
includ
highli
conserv
critic
epitop
residu
defin
loss
bind
alanin
substitut
mutat
prolin
result
loss
neutral
activ
similarli
inhibit
glycan
cap
cleavag
could
molecular
basi
neutral
activ
mab
two
nonconserv
residu
whose
mutat
alanin
decreas
bind
figur
directli
contact
paratop
within
cleavag
site
sudv
gp
natur
mutat
affect
activ
similar
way
lower
ec
bind
reduc
neutral
potenc
figur
suggest
destabil
epitop
adjac
mutat
fab
alon
fab
bound
state
domain
ctermin
gp
loop
displac
structur
mimick
loop
figur
lc
contact
hydrophob
interact
loop
residu
contact
residu
make
possibl
hbond
backbon
figur
anchor
mab
inner
chalic
gp
figur
observ
destabil
dissoci
gp
trimer
figur
dissoci
limit
presenc
stalkspecif
mab
use
stabil
gp
cryoem
unclear
whether
disrupt
seen
solubl
gp
also
occur
membraneanchor
gp
whether
contribut
synergi
analysi
interact
structur
bound
gp
show
loop
make
addit
contact
beyond
pocket
glycan
cap
intact
contact
includ
c
interact
lc
residu
residu
enlarg
view
epitop
orang
yellow
cyan
overlaid
unligand
structur
ebov
gp
dmucdtm
gray
green
e
loop
base
helix
glycan
cap
present
unligand
gp
structur
gray
green
overlaid
bound
gp
structur
orang
region
interfer
bind
shown
red
cross
f
posit
helix
bound
gp
structur
cyan
overlaid
unligand
gp
helix
magenta
g
h
cartoon
propos
cooper
mechan
gp
bind
cocktail
alon
bind
weakli
g
presenc
chang
caus
engag
bind
strongli
h
see
also
figur
tabl
video
figur
mab
bind
gp
manner
mimic
interact
unligand
gp
loop
residu
make
contact
along
sheet
form
sever
hydrogen
bond
within
extend
beta
sheet
glycan
cap
black
dot
line
mimic
interact
region
unligand
structur
shown
anoth
key
contact
shown
cradl
within
hydrophob
pocket
form
tip
b
interact
loop
residu
pocket
residu
mimic
interact
loop
residu
unligand
structur
addit
interact
glycan
cap
intact
hydrophob
patch
base
helix
shown
legend
continu
next
page
base
loop
residu
bound
displac
loop
mimick
interact
loop
unligand
structur
figur
residu
highli
conserv
among
ebov
bdbv
sudv
gp
note
previou
studi
identifi
key
epitop
residu
given
mutat
reduc
bind
gp
therefor
effici
bind
must
overcom
interfer
loop
helix
contain
glycan
cap
structur
figur
two
fab
cocktail
bound
gp
region
displac
glycan
cap
pull
back
along
loop
allow
effici
bind
figur
howev
structur
bound
gp
alon
glycan
cap
displac
degre
bound
rather
reminisc
structur
unligand
gp
although
strand
displac
replac
loop
larg
intact
bound
base
ifl
block
pocket
figur
compar
solvent
exclus
unligand
gp
gp
complex
alon
appear
similar
except
domain
region
bound
still
exclud
helix
displac
figur
consist
observ
fulli
potenti
bind
data
suggest
cocktail
alon
larg
respons
complet
displac
loop
well
displac
helix
cocktail
wherea
act
displac
domain
ctermin
portion
loop
allevi
structur
kinet
restraint
effici
bind
figur
conclud
structur
remodel
princip
mechan
enhanc
gp
bind
ebolaviru
neutral
cocktail
two
cooper
natur
occur
human
mab
figur
video
analysi
molecular
interact
gp
illustr
mab
use
molecular
mimicri
wherebi
bind
gp
manner
analog
interact
unligand
gp
thu
interfac
sheet
glycan
cap
mimick
interact
region
sheet
figur
interfac
pocket
residu
mimick
interact
loop
unligand
gp
figur
togeth
experi
defin
key
molecular
featur
mediat
bind
cooper
cocktail
two
broadli
neutral
human
mab
mab
cocktail
protect
nonhuman
primat
evd
next
use
nhp
rhesu
macaqu
ebov
challeng
model
recapitul
mani
key
featur
evd
human
geisbert
et
al
bennett
et
al
determin
efficaci
treatment
cocktail
rhesu
macaqu
assign
one
treatment
group
five
anim
intramuscular
challeng
lethal
target
dose
plaqueform
unit
pfu
kikwit
variant
ebov
nhp
treatment
group
receiv
intraven
two
mgkg
dose
cocktail
mixtur
space
day
apart
day
infect
addit
anim
studi
contemporan
control
left
untreat
along
ten
histor
untreat
control
day
postinfect
dpi
median
surviv
inocul
rout
stock
viru
control
untreat
anim
develop
high
clinic
score
succumb
diseas
day
infect
twodos
therapeut
cocktail
treatment
provid
complet
protect
nhp
mortal
clinic
sign
evd
figur
first
treatment
day
infect
three
five
nhp
treatmentdesign
group
also
control
untreat
nhp
develop
detect
viremia
plasma
titer
rang
log
log
genom
equival
geq
per
ml
measur
qrtpcr
figur
plasma
titer
infecti
viru
assess
plaqu
assay
day
infect
limit
detect
anim
howev
day
infect
viral
load
untreat
anim
includ
nhp
control
studi
histor
control
high
log
pfuml
log
geq
ml
figur
concord
full
protect
day
infect
treat
nhp
includ
three
regist
highli
virem
day
infect
longer
detect
viremia
plasma
variou
tissu
harvest
treat
anim
day
infect
qrtpcr
analysi
detect
infecti
noninfecti
neutral
particl
yet
clear
reveal
viru
confirm
activ
ebov
infect
nhp
treatment
group
treatment
tabl
next
assess
chang
blood
chemistri
typic
associ
evd
character
efficaci
mab
cocktail
treatment
tabl
liver
enzym
alanin
aminotransferas
alt
gamma
glutamyl
transferas
ggt
alkalin
phosphatas
alp
indic
evd
elev
untreat
nhp
day
infectionth
peak
viremia
diseas
figur
treat
anim
show
sign
acut
liver
injuri
day
infect
later
time
point
display
low
amount
alt
ggt
alp
compar
untreat
nhp
figur
tabl
probe
possibl
select
escap
mutant
presenc
cocktail
assess
sever
peripher
tissu
presenc
live
infecti
orang
curv
indic
treat
black
curv
indic
untreat
anim
ten
histor
control
gray
shown
compar
purpos
black
dot
line
b
indic
clinic
score
threshold
euthanasia
black
dot
line
c
indic
limit
detect
lod
genom
equival
geq
measur
repres
mean
technic
duplic
see
also
figur
tabl
viru
cover
nhp
use
rang
tissu
higher
number
viral
genom
detect
qrtpcr
test
tissu
treat
nhp
confirm
neg
live
viru
day
infect
show
cocktail
treatment
provid
steril
immun
figur
human
igg
captur
elisa
serum
sampl
reveal
circul
cocktail
mab
treat
nhp
rang
mgml
figur
given
relev
high
mab
concentr
strong
cooper
interact
figur
cooper
mediat
cocktail
like
contribut
effect
treatment
summari
twoantibodi
cocktail
deploy
multipl
function
mechan
neutral
two
mab
synergi
mediat
cocktail
fcmediat
effector
function
exhibit
demonstr
high
potenc
revert
evd
nhp
report
determin
cooper
improv
viru
bind
neutral
cocktail
studi
defin
essenti
featur
cooper
mab
implic
design
therapeut
cocktail
show
mab
enabl
cooper
neutral
ebolavirus
gener
immun
respons
human
evd
survivor
identifi
epitop
cooper
human
mab
describ
remodel
glycan
cap
structur
gp
mechan
mab
cooper
identifi
molecular
mimicri
mechan
ebolaviru
gp
recognit
human
mab
show
cocktail
two
cooper
human
mab
could
mediat
enhanc
activ
heterolog
ebolavirus
demonstr
therapeut
effect
twoantibodi
cocktail
nhp
evd
identifi
fceffector
function
variant
gp
baseand
glycancapspecif
mab
mediat
protect
evd
nhp
date
monotherapi
treatment
treatment
two
fulli
human
mab
cocktail
af
evalu
clinic
develop
af
twoantibodi
cocktail
panebolaviru
activ
demonstr
efficaci
nhp
bornholdt
et
al
threeantibodi
cocktail
pascal
et
al
singl
mab
specif
receptor
bind
site
gp
corti
et
al
monospecif
ebov
recent
assess
field
drc
outbreak
human
evd
earli
treatment
associ
reduct
mortal
rate
natur
news
ebov
antibodi
describ
shown
far
protect
nhp
monotherapi
set
even
protect
mediat
cocktail
better
mediat
alon
corti
et
al
cocktail
also
potenti
benefit
avoid
high
risk
viru
escap
inher
monotherapi
approach
target
crossreact
epitop
might
anoth
approach
reduc
viral
escap
given
conserv
region
like
critic
viru
function
therefor
singl
broad
cocktail
least
effect
exist
monospecif
cocktail
ebov
would
practic
cocktail
formul
add
principl
cooper
eg
incorpor
pair
noncompet
potent
neutral
mab
togeth
exhibit
enhanc
activ
therefor
addit
reactiv
breadth
extend
bdbv
sudv
cocktail
incorpor
four
princip
activ
homolog
ebov
independ
neutral
activ
enhanc
combin
activ
synergi
cocktail
fcmediat
effector
function
comparison
histor
nhp
studi
af
qualifi
cocktail
highli
protect
ebov
next
studi
determin
whether
cocktail
protect
nhp
heterolog
ebolavirus
mab
cocktail
act
sever
mechan
gp
bind
studi
demonstr
strongest
enhanc
cocktail
achiev
higher
mab
concentr
given
rel
high
concentr
circul
mab
intraven
administr
igg
treat
nhp
suggest
enabl
cooper
one
mechan
like
contribut
effect
treatment
along
viru
neutral
fcmediat
function
individu
mab
cocktail
potent
neutral
ebov
bdbv
therefor
unlik
nonneutr
synergist
mab
howel
et
al
synergi
ad
necessari
featur
achiev
neutral
cocktail
synergist
cocktail
formul
two
neutral
mab
would
like
effici
counteract
viral
escap
cooper
cocktail
mediat
recognit
glycan
cap
epitop
conform
epitop
span
ifl
sever
studi
identifi
ifl
site
vulner
potent
mab
act
sole
neutral
protect
wec
et
al
mab
recogn
glycan
cap
epitop
consid
inferior
therapeut
develop
possibl
crossreact
solubl
gp
sgp
mohan
et
al
recent
studi
howev
suggest
indispens
role
fcmediat
effector
function
protect
ebov
glycancapspecif
mab
unknown
whether
function
eg
neutral
activ
fc
engag
cocktail
two
mab
specif
essenti
suffici
efficaci
nhp
studi
suggest
function
could
import
viru
control
evd
prevent
show
cocktail
fcfunctioncompet
form
glycancapspecif
function
impair
form
neutral
iflspecif
mediat
therapeut
protect
nhp
key
structur
aspect
work
find
remodel
glycan
cap
necessari
effici
bind
potent
mab
vulner
epitop
remodel
facilit
presenc
mab
therefor
work
defin
cooper
interact
mab
two
major
epitop
specif
gp
recognit
unveil
cooper
bind
gp
mechan
enhanc
ebolaviru
neutral
protect
principl
mabantigen
interact
demonstr
ebolaviru
could
aid
design
therapeut
cocktail
viral
target
detail
method
provid
onlin
version
paper
includ
follow
zivanov
j
nakan
forsberg
bo
kimaniu
hagen
wj
lindahl
e
schere
sh
new
tool
autom
highresolut
cryoem
structur
determin
elif
immobil
papain
thermofish
cat
brefeldin
sigma
aldrich
cat
golgistop
bd
bioscienc
cat
step
tactin
inform
request
resourc
reagent
direct
fulfil
lead
contact
jame
e
crow
jr
jamescrow
vumcorg
materi
describ
paper
avail
distribut
uniform
biolog
materi
transfer
agreement
master
agreement
develop
nih
simplifi
transfer
biolog
research
materi
human
sampl
human
pbmc
obtain
survivor
evd
epidem
nigeria
male
human
survivor
evd
outbreak
nigeria
age
infect
age
pbmc
collect
pbmc
collect
ill
resolv
follow
written
inform
consent
time
blood
collect
plasma
sampl
test
qrtpcr
found
neg
presenc
viral
rna
studi
approv
institut
review
board
vanderbilt
univers
medic
center
monkey
femal
origin
human
male
origin
jurkat
human
male
origin
cell
line
obtain
american
type
cultur
collect
atcc
cell
cultur
minim
essenti
medium
mem
thermofish
scientif
supplement
fetal
bovin
serum
fb
hyclon
penicillinstreptomycin
co
c
jurkat
cell
cultur
rpmi
gibco
medium
supplement
heatinactiv
fb
gibco
glutamax
gibco
unitsml
penicillin
mgml
streptomycin
gibco
c
co
line
nonsecret
mousehuman
trioma
cell
line
sex
inform
avail
gener
fuse
murin
myeloma
cell
line
human
myeloma
cell
line
yield
intermedi
heteromyeloma
follow
fusion
human
lymphocyt
cell
line
cultur
describ
previous
yu
et
al
cell
line
human
femal
origin
stablytransfect
express
snaptag
ebov
gp
describ
previous
domi
et
al
expicho
hamster
femal
origin
freestyl
human
femal
origin
cell
line
purchas
thermofish
scientif
cultur
accord
manufactur
protocol
jurkatebov
gp
cell
line
test
monthli
basi
mycoplasma
found
neg
case
authent
ebovegfp
mouseadapt
ebov
mayinga
ebovma
genbank
sudv
strain
gulu
describ
previous
bray
et
al
sanchez
rollin
towner
et
al
chimer
infecti
ebovbdbvgp
ebov
sudvgp
virus
express
egfp
obtain
replac
gene
encod
ebov
gp
bdbv
genbank
sudv
genbank
respect
ilinykh
et
al
sevento
eightweek
old
femal
balbc
mice
obtain
jackson
laboratori
femal
mice
obtain
tacon
bioscienc
mice
hous
microisol
cage
provid
food
water
ad
libitum
challeng
studi
conduct
maximum
contain
anim
biosafeti
level
facil
galveston
nation
laboratori
utmb
anim
protocol
test
mab
mice
approv
fourto
sixyear
old
male
n
femal
n
rhesu
macaqu
use
studi
obtain
primgen
nhp
research
adher
principl
state
eighth
edit
guid
care
use
laboratori
anim
facil
research
conduct
univers
texa
medic
branch
utmb
fulli
accredit
associ
assess
accredit
laboratori
anim
care
intern
approv
offic
laboratori
anim
welfar
assur
gener
human
b
cell
hybridoma
produc
mab
pbmc
leukopak
isol
ficollhistopaqu
densiti
gradient
centrifug
cell
cryopreserv
vapor
phase
liquid
nitrogen
use
ebov
gpreactiv
memori
b
cell
label
recombin
ebov
gp
protein
produc
drosophila
schneider
cell
describ
purifi
fluoresc
activ
cell
sort
fac
describ
previous
bornholdt
et
al
step
result
sort
ebov
gpreactiv
memori
b
cell
human
b
cell
hybridoma
gener
describ
previous
yu
et
al
modif
briefli
facsisol
gpreactiv
b
cell
bulkexpand
irradi
nih
cell
engin
express
human
baff
medium
stemcel
technolog
supplement
cpg
inhibitor
sigmaaldrich
cyclosporin
sigmaaldrich
day
cell
bulkfus
myeloma
cell
use
establish
electrofus
techniqu
yu
et
al
result
gener
individu
hybridoma
line
fusion
reaction
hybridoma
line
cultur
clonacellhi
medium
e
stemcel
technolog
supplement
hat
hypoxanthineaminopterinthymidin
media
supplement
sigmaaldrich
plate
day
screen
supernat
antibodi
product
screen
strategi
identifi
partner
mab
therapeut
cocktail
previou
work
use
jurkat
cell
surfac
display
ebov
gp
assess
competitionbind
group
gp
reactiv
mab
isol
human
survivor
evd
outbreak
drc
studi
reveal
bind
two
broadlyreact
glycan
cap
specif
mab
increas
bind
broadlyneutr
highli
protect
basespecif
mab
develop
cooper
mab
cocktail
perform
comprehens
screen
individu
gpreactiv
b
cell
line
supernat
studi
previou
studi
drc
outbreak
survivor
identifi
suitabl
partner
mab
potent
basespecif
mab
criteria
downselect
partner
mab
candid
includ
high
neutral
activ
live
pathogen
viru
neutral
least
ebov
b
broad
reactiv
ebov
bdbv
sudv
gp
c
synergist
activ
defin
abil
mab
enhanc
bind
least
enhanc
compar
bind
basespecif
mab
alon
efficaci
monotherapi
mice
protect
live
ebov
challeng
supernat
well
cultur
plate
expand
hybridoma
line
first
assess
neutral
activ
live
ebov
use
one
supernat
dilut
plate
format
detail
neutral
assay
section
next
hybridoma
line
fulli
neutral
ebov
supernat
dilut
test
assess
elisa
reactiv
recombin
ebov
bdbv
sudv
gp
broadlyreact
clone
identifi
test
neutral
activ
live
bdbv
sudv
hybridoma
cell
line
produc
crossreact
neutral
mab
mab
react
three
gp
neutral
least
ebov
bdbv
clone
biolog
singlecel
fluorescenceactiv
cell
sort
hybridoma
expand
medium
e
stemcel
technolog
confluent
flask
corn
purifi
mab
test
use
competitionbind
assay
intact
jurkatebov
gp
thermolysin
cleav
jurkatebov
gp
cl
identifi
major
antigen
site
identifi
mab
compet
refer
glycan
cap
specif
mab
davidson
et
al
flyak
et
al
intact
gp
b
recogn
intact
cleav
gp
assess
cooper
bind
jurkat
cell
surfac
display
ebov
gp
presenc
gp
basespecif
mab
describ
screen
approach
result
identif
broadlyreact
glycan
cap
regionspecif
mab
antibodi
potent
neutral
ebov
bdbv
offer
partial
protect
surviv
vivo
mice
lethal
challeng
live
ebov
mab
show
highest
cooper
base
featur
select
test
cocktail
isotyp
subclass
secret
antibodi
determin
use
murin
antihuman
mous
antibodi
conjug
alkalin
phosphatas
southern
biotech
antibodi
heavyand
lightchain
variabl
region
gene
sequenc
rna
obtain
hybridoma
line
clone
biolog
flow
cytometr
sort
total
rna
extract
use
rneasi
mini
kit
qiagen
modifi
race
rapid
amplif
cdna
end
approach
use
turchaninova
et
al
briefli
ml
total
rna
mix
cdna
synthesi
primer
mix
mm
incub
min
c
decreas
incub
temperatur
c
anneal
synthesi
primer
min
incub
mixtur
contain
firststrand
buffer
clontech
dtt
mm
templat
switch
oligo
mm
dntp
solut
mm
smartscrib
revers
transcriptas
clontech
ad
primerann
total
rna
reaction
incub
min
c
firststrand
synthesi
reaction
purifi
use
ampur
size
select
magnet
bead
kit
ratio
beckman
coulter
follow
singl
pcr
amplif
reaction
contain
ml
firststrand
cdna
high
fidel
mastermix
neb
dntp
mm
forward
univers
primer
mm
revers
primer
mix
mm
heavychain
mix
mm
lightchain
mix
subject
thermal
cycl
follow
condit
initi
denatur
min
follow
cycl
denatur
c
anneal
c
extens
c
follow
final
extens
step
c
min
primer
sequenc
use
protocol
previous
describ
turchaninova
et
al
first
pcr
reaction
purifi
use
ampur
size
select
magnet
bead
kit
ratio
beckman
coulter
amplicon
librari
prepar
accord
pacif
bioscienc
multiplex
smrt
sequenc
protocol
sequenc
pacif
bioscienc
sequel
platform
raw
sequenc
data
demultiplex
circular
consensu
sequenc
cc
determin
use
pacif
bioscienc
smrt
analysi
tool
suit
ident
gene
segment
cdr
mutat
germlin
determin
align
use
immunogenet
databas
giudicelli
lefranc
recombin
mab
product
cdna
encod
gene
heavi
light
chain
clone
dna
plasmid
express
vector
encod
fabheavi
chain
mclean
et
al
transform
e
coli
cell
mab
protein
produc
transient
transfect
expicho
cell
follow
manufactur
protocol
purifi
filter
cultur
supernat
fast
protein
liquid
chromatographi
fplc
ekta
instrument
use
hitrap
mabselect
sure
column
ge
healthcar
life
scienc
purifi
mab
buffer
exchang
pb
filter
use
steril
pore
size
filter
devic
millipor
concentr
store
aliquot
c
use
ectodomain
ebov
gp
dtm
residu
strain
makona
genbank
bdbv
gp
dtm
residu
strain
uganda
genbank
sudv
gp
dtm
residu
strain
gulu
genbank
marv
gp
dtm
residu
strain
genbank
express
purifi
describ
well
microtit
plate
coat
purifi
recombin
ebov
bdbv
sudv
marv
gp
dtm
incub
c
overnight
plate
block
nonfat
dri
milk
normal
goat
serum
dpb
contain
dpbst
h
mab
screen
assay
hybridoma
cultur
supernat
dilut
block
buffer
ad
well
incub
h
ambient
temperatur
bound
antibodi
detect
use
goat
antihuman
igg
conjug
hrp
horseradish
peroxidas
southern
biotech
tmb
tetramethylbenzidin
substrat
thermofish
scientif
color
develop
monitor
hydrochlor
acid
ad
stop
reaction
absorb
measur
nm
use
spectrophotomet
biotek
doserespons
crossreact
assay
serial
dilut
purifi
mab
appli
well
triplic
quadrupl
mab
bind
detect
detail
octet
red
tm
instrument
fortkbio
pall
use
assess
bind
kinet
indic
mab
ebov
gp
streptavidin
sensor
fort
bio
use
captur
biotinyl
ebov
gp
mgml
kinet
buffer
pb
contain
bovin
serum
albumin
bsa
sigmaaldrich
indic
bind
perform
use
serial
twofold
dilut
mab
baselin
dissoci
step
carri
kinet
buffer
c
per
vendor
recommend
kinet
bind
data
adequ
describ
bind
model
account
trimer
natur
immobil
gp
bival
igg
analyt
associ
stoichiometri
like
reflect
complex
avid
effect
therefor
data
repres
appar
k
valu
k
app
tabl
previous
describ
davidson
et
al
bind
jurkat
cell
surfac
display
ebov
bdbv
sudv
gp
assess
mab
directli
fluorescentlylabel
briefli
mab
label
nh
ester
thermofish
scientif
follow
manufactur
protocol
label
mab
buffer
exchang
pb
use
desalt
zeba
column
thermofish
scientif
store
c
bsa
sigmaaldrich
sodium
azid
cell
wash
incub
buffer
contain
dpb
dulbecco
phosphatebuff
salin
heatinactiv
fb
mm
edta
ethylenediaminetetraacet
acid
sodium
salt
ph
centrifug
x
g
min
ambient
temperatur
antibodi
stain
g
cell
ad
per
well
vbottom
plate
corn
ml
incub
buffer
serial
dilut
antibodi
ad
cell
triplic
quadrupl
total
volum
ml
per
well
follow
h
incub
room
temperatur
c
experi
unbound
antibodi
remov
wash
ml
incub
buffer
stain
cell
measur
flow
cytometr
analysi
use
intellicyt
iqu
screener
plu
high
throughput
cytomet
intellicyt
corp
data
event
acquir
data
analyz
forecyt
intellicyt
corp
softwar
dead
cell
exclud
analysi
basi
forward
side
scatter
gate
viabl
cell
popul
bind
untransduc
jurkat
cell
bind
dengu
antigenspecif
mab
denv
serv
neg
control
experi
experi
cell
fix
paraformaldehyd
pfa
dpb
stain
flow
cytometr
analysi
assess
bind
mab
cleav
gp
jurkatebov
bdbv
sudv
gp
cell
treat
mgml
thermolysin
promega
pb
min
c
cell
stain
flow
cytometr
analysi
perform
describ
reaction
inhibit
wash
cell
incub
buffer
contain
dpb
heatinactiv
fb
mm
edta
ph
bind
untransduc
jurkat
mock
uncleav
jurkatebov
gp
serv
control
ec
valu
satur
bind
mab
gp
cl
determin
use
prism
softwar
graphpad
log
transform
mab
concentr
median
fluoresc
intens
mfi
valu
use
sigmoid
doserespons
nonlinear
regress
analysi
nonsatur
mab
bind
observ
intact
gp
ec
valu
calcul
linear
regress
analysi
use
ec
maximum
respons
bmax
valu
determin
satur
bind
gp
cl
cooper
bind
cell
surfac
display
gp
assay
perform
describ
previous
briefli
jurkatebov
bdbv
sudv
gp
cell
incub
triplic
first
mab
alon
typic
gpbase
specif
mab
label
mab
titrat
fix
concentr
typic
mgml
unlabel
second
mab
typic
gp
glycan
cap
specif
mab
cell
wash
antibodi
bind
analyz
flow
cytometri
use
intellicyt
iqu
screener
plu
flow
cytomet
background
valu
determin
bind
fluoresc
label
mab
untransduc
mock
jurkat
cell
maxim
valu
satur
bind
estim
doserespons
bind
curv
gpbase
specif
mab
respect
cell
surfac
display
cleav
gp
gp
cl
base
similar
ratio
conjug
result
express
percent
maxim
bind
minu
background
signal
mock
control
test
condit
label
mab
epitop
map
use
ebov
gp
alaninescan
mutat
librari
epitop
map
carri
describ
previous
davidson
et
al
comprehens
highthroughput
alanin
scan
shotgun
mutagenesi
carri
express
construct
ebov
gp
lack
mucinlik
domain
residu
base
yambukumayinga
variant
gp
sequenc
mutagen
gp
residu
creat
librari
clone
repres
individu
point
mutant
residu
chang
alanin
alanin
residu
chang
serin
result
librari
cover
target
residu
array
plate
one
mutant
per
well
transfect
cell
allow
express
h
cell
unfix
fix
pfa
incub
primari
antibodi
secondari
antibodi
jackson
immunoresearch
laboratori
wash
cellular
fluoresc
detect
use
intellicyt
flow
cytomet
mab
reactiv
mutant
ebov
gp
clone
calcul
rel
wildtyp
ebov
gp
reactiv
subtract
signal
mocktransfect
control
normal
signal
wildtyp
gptransfect
control
mutat
residu
within
clone
identifi
critic
mab
epitop
support
reactiv
test
mab
support
reactiv
control
ebov
mab
counterscreen
strategi
facilit
exclus
gp
mutant
misfold
local
exhibit
express
defect
davidson
doranz
gener
escap
mutant
pfu
ebovegfp
combin
dilut
respect
mab
start
mgml
ubottom
plate
incub
h
c
mixtur
appli
cell
monolay
cultur
plate
incub
h
supernat
remov
freshlydilut
mab
ad
concentr
ml
mem
supplement
fb
plate
incub
day
c
virus
replic
presenc
highest
concentr
mab
determin
monitor
egfp
fluoresc
microscopi
collect
twenti
ml
aliquot
incub
dilut
mab
start
mgml
virus
propag
presenc
mab
describ
procedur
repeat
mab
dilut
start
mgml
virus
replic
highest
mab
concentr
amplifi
cell
cultur
monolay
plate
presenc
mab
mgml
day
cellular
rna
extract
use
trizol
reagent
cdna
copi
viral
rna
encod
gp
amplifi
rtpcr
sequenc
verifi
isol
escap
mutant
pfu
virus
mem
supplement
fb
triplic
combin
ubottom
plate
twofold
dilut
mab
start
mgml
incub
h
c
virusantibodi
mixtur
appli
triplic
cell
cultur
monolay
plate
incub
h
c
wash
mem
overlaid
ml
mem
contain
fb
methylcellulos
incub
h
c
plate
fix
phosphatebuff
formalin
fisher
plaqu
count
use
fluoresc
microscopi
viru
neutral
assay
perform
highthroughput
format
use
recombin
ebovegfp
chimer
ebov
virus
gp
replac
counterpart
bdbv
sudv
describ
previous
ilinykh
et
al
briefli
fourfold
dilut
respect
mab
start
mgml
mix
triplic
pfu
viru
ubottom
plate
incub
h
c
mixtur
appli
cell
monolay
cultur
plate
incub
four
day
c
absenc
mab
neutral
activ
infect
result
uniform
egfp
fluoresc
monolay
cell
readili
detect
fluoresc
microscopi
fluoresc
measur
use
synergi
ht
micropl
reader
biotek
assess
cooper
neutral
sudv
cocktail
two
mab
viru
incub
increas
concentr
alon
titrat
fix
concentr
mgml
triplic
screen
escap
mutat
presenc
individu
mab
cocktail
use
highthroughput
quantit
realtim
cell
analysi
assay
xcellig
analyz
acea
bioscienc
inc
assess
kinet
chang
cell
physiolog
includ
virusinduc
cytopath
effect
cpe
fifti
ml
cell
cultur
medium
dmem
supplement
fb
ad
well
eplat
obtain
background
read
eighteen
thousand
cell
ml
cell
cultur
medium
seed
per
well
plate
place
analyz
measur
taken
automat
everi
min
sensogram
visual
use
rtca
softwar
version
acea
bioscienc
inc
first
passag
rvsv
ebov
gp
rvsvsudv
gp
virus
moi
pfu
per
well
mix
eight
twofold
dilut
individu
mab
cocktail
mab
ratio
start
mgml
total
volum
ml
incub
h
c
h
seed
cell
virusmab
mixtur
ad
replic
cell
eplat
well
contain
viru
absenc
mab
well
contain
vero
cell
medium
includ
plate
control
plate
measur
continu
everi
min
h
assess
viru
neutral
ten
ml
aliquot
well
virus
replic
highest
mab
concentr
pfu
use
repeat
passag
total
passag
rvsvebov
gp
passag
rvsvsudv
gp
escap
mutant
identifi
cpe
well
contain
typic
neutral
concentr
mab
verifi
escap
mutat
isol
virus
test
mgml
individu
mab
cocktail
use
rtca
neutral
assay
sequenc
control
includ
virus
late
passag
escap
neutral
presenc
cocktail
virus
incub
presenc
control
mab
denv
virus
assess
individu
mab
denv
cocktail
sequenc
rapid
fluorometr
antibodymedi
cytotox
assay
rfadcc
antibodydepend
cellmedi
cytotox
adcc
activ
ebov
gpreactiv
igg
fab
quantifi
ebovadapt
modif
rfadcc
assay
domi
et
al
orlandi
et
al
briefli
target
cell
line
made
transfect
cell
fulllength
dna
express
gp
ebovkikwit
isol
follow
transfect
two
separ
dna
construct
express
egfp
chimer
tag
protein
new
cell
line
design
ebov
egfp
express
ebovkikwit
gp
plasma
membran
egfp
cytoplasm
snaptag
specif
label
snapsurfac
neb
cell
surfac
domi
et
al
recombin
form
human
antiebov
gp
mab
neutral
antibodi
ibt
bioservic
use
posit
control
unrel
human
mab
denv
neg
control
adcc
activ
quantifi
incub
threefold
serial
dilut
mab
ebov
egfp
target
cell
min
ambient
temperatur
ad
human
pbmc
effector
cell
h
c
cell
wash
pb
fix
pfa
stain
analyz
lsrii
fortessa
flow
cytomet
bd
bioscienc
data
analysi
perform
flowjo
softwar
tree
star
inc
percentag
cytotox
mab
determin
number
target
cell
lose
egfp
signal
virtu
adcc
retain
surfac
express
glycan
ad
trim
fit
em
densiti
use
model
best
statist
follow
manual
adjust
coot
emsley
et
al
follow
final
round
refin
rosetta
includ
glycan
restrain
backbon
coordin
ebov
gp
dmucdtm
makona
complex
alon
addit
refin
phenix
perform
ideal
geometri
glycan
valid
use
pdbcare
uttek
von
der
lieth
privat
agirr
et
al
model
figur
gener
use
ucsf
chimera
pettersen
et
al
estim
chang
gp
solvent
exclus
upon
fab
bind
unligand
gp
structur
pdb
bound
respect
fab
use
creat
surfac
map
ucsf
chimera
pettersen
et
al
normal
glyxgli
tripeptid
bendel
et
al
determin
normal
solvent
exclud
surfac
se
epitop
map
use
peptid
fragment
hydrogendeuterium
exchang
mass
spectrometri
hdxm
maxim
peptid
sequenc
coverag
optim
digest
quench
condit
determin
prior
deuter
studi
briefli
ebov
gp
dtm
ebov
gp
cl
sampl
dilut
dpb
buffer
mm
nacl
mm
kh
po
ph
c
quench
formic
acid
vv
contain
variou
concentr
guanidin
hydrochlorid
guhcl
tri
phosphin
tcep
eight
guhcl
tcep
pb
ph
gave
optim
peptid
coverag
map
hydrogendeuterium
exchang
reaction
initi
dilut
protein
sampl
dpb
buffer
ratio
vv
prior
quench
onlin
pepsin
digest
nondeuter
sampl
serv
control
use
water
nanoacqu
uplc
system
hdx
manag
water
corp
sampl
inject
onto
immobil
pepsin
column
water
enzym
tm
digest
perform
c
psi
flow
mlmin
formic
acid
h
result
peptid
collect
vanguard
beh
mm
guard
column
water
corp
separ
water
beh
mm
mm
x
mm
column
use
gradient
acetonitril
min
column
coupl
water
xevo
instrument
eluent
electrospray
ms
e
scan
perform
lockmass
acquisit
leucin
enkephalin
mz
capillari
set
sourc
temperatur
c
desolv
temperatur
c
desolv
ga
lh
instrument
scan
mz
rang
experi
carri
triplic
water
proteinlynx
lgobal
server
softwar
water
corp
use
identifi
peptid
ion
fdr
use
nonspecif
proteas
cleavag
minimum
number
fragment
ion
match
per
peptid
three
oxid
methionin
variabl
modif
dynamx
water
corp
use
analysi
mass
spectra
nondeuter
sampl
equilibriumdeuter
backexchang
control
sampl
serv
control
centroid
isotop
envelop
nondeuter
function
deuter
fulli
deuter
peptid
measur
use
dxm
explor
convert
correspond
deuter
level
correct
backexchang
crystallographi
structur
determin
ebov
gp
cocrystal
express
mucinlik
domaindelet
gp
gp
dmuc
drosophila
cell
use
singl
pmtpuro
plasmid
encod
ctermin
streptag
construct
lack
transmembran
domain
protein
purifi
use
streptrap
hp
affin
chromatographi
column
ge
healthcar
life
scienc
follow
cleavag
strep
tag
enterokinas
cleavag
site
use
ekmax
thermofish
scientif
prepar
gp
cl
purifi
gp
dmuc
incub
thermolysin
overnight
room
temperatur
mimic
endosom
cathepsin
cleavag
follow
purif
use
superdex
increas
gl
sec
column
ge
healthcar
life
scienc
fab
cocrystal
ebov
gp
cl
prepar
incub
igg
papain
h
c
digest
quench
use
mm
iodoacetamid
fab
purifi
reaction
mixtur
use
monoq
gl
ionexchang
column
ge
healthcar
life
scienc
follow
purif
use
superdex
increas
gl
sec
column
ge
healthcar
life
scienc
gp
cl
fab
complex
obtain
incub
gp
cl
molar
excess
fab
overnight
c
follow
purif
use
superdex
increas
gl
sec
column
ge
healthcar
life
scienc
complex
screen
crystal
use
dougla
instrument
protein
crystal
solut
hepe
ph
ammonium
sulfat
diffract
data
f
resolut
collect
beamlin
advanc
photon
sourc
diffract
imag
process
use
imosflm
batty
et
al
scale
use
aimless
evan
murshudov
molecular
replac
model
build
structur
refin
carri
use
phenix
suit
program
chain
g
h
pdb
entri
use
molecular
replac
search
model
gp
cl
chain
z
pdb
entri
use
search
model
fab
follow
model
prune
use
sculptor
bunkyczi
read
molecular
graphic
applic
coot
emsley
et
al
use
model
inspect
manual
refin
singl
gp
cl
monom
singl
fab
contain
within
asymmetr
unit
crystal
crystal
symmetri
appli
gener
model
biolog
relev
trimer
shown
figur
descript
statist
mean
sem
mean
sd
determin
continu
variabl
note
surviv
curv
estim
use
kaplan
meier
method
curv
compar
use
twosid
log
rank
test
mantelcox
subject
right
censor
surviv
end
studi
ec
valu
mab
bind
determin
log
transform
antibodi
concentr
use
sigmoid
doserespons
nonlinear
regress
analysi
neutral
assay
ic
valu
calcul
log
transform
antibodi
concentr
use
nonlinear
fit
analysi
effect
antibodi
composit
gp
bind
singl
mab
twoantibodi
mixtur
p
valu
estim
overal
test
untransform
mfi
flow
cytometr
valu
use
twoway
anova
neutral
assay
mab
synergi
cocktail
quantifi
compusyn
softwar
use
approach
estim
combin
index
ci
defin
effect
drug
combin
chou
ci
valu
calcul
test
concentr
mab
combin
ci
valu
consid
evid
synergi
viral
titer
plasma
compar
use
wilcoxon
signedrank
test
twotail
column
median
compar
valu
equal
limit
detect
plaqu
assay
log
pfuml
p
consid
signific
technic
biolog
replic
indic
figur
legend
statist
analys
perform
use
prism
graphpad
ebov
gp
cl
fab
crystal
structur
ebov
gp
dmuc
dtm
makona
fab
cryoem
structur
ebov
gp
dmuc
dtm
makona
fab
structur
deposit
pdb
access
code
respect
access
number
neg
stain
cryoem
reconstruct
report
paper
deposit
electron
microscopi
data
bank
access
number
emdb
see
key
resourc
tabl
detail
respect
relev
data
includ
manuscript
sourc
data
display
item
provid
key
resourc
tabl
